ArticleCritical care (London, England)2026
Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rate control in septic shock-associated atrial fibrillation: flow, not heart rate alone, should define haemodynamic success.Critical care (London, England) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew-onset atrial fibrillation (NOAF) frequently complicates septic shock and is associated with haemodynamic instability, prolonged intensive care unit stay, and increased mortality. Despite its clinical relevance, guidance on heart rate (HR) management remains limited, particularly regarding the use of ultra-short-acting β₁-blockers. To reduce variability in clinical practice, a European multidisciplinary panel developed a consensus on the management of atrial fibrillation in septic shock, with a focus on landiolol.
methodsA modified RAND/UCLA Delphi methodology was applied. Nine European experts in intensive care, anaesthesiology, and cardiology participated in two Delphi rounds. Fifty-five statements across nine thematic areas were evaluated using a 9-point Likert scale. Consensus was predefined as ≥ 80% agreement within the same scoring range.
resultsOverall, 70.9% of statements achieved consensus and were included in the final recommendations. Consensus supported the correction of reversible triggers of atrial fibrillation, haemodynamic assessment before HR control, and an individualised cardioversion strategy. Landiolol was endorsed for HR control in selected septic shock patients with NOAF, given its high β₁-selectivity and rapid titratability. Consensus supported initiation without bolus, starting at low doses gradually titrated, to an initial HR target below 110 bpm, guided by close haemodynamic and echocardiographic monitoring. No consensus was reached on the optimal duration of landiolol therapy or its use in patients with severe ventricular dysfunction.
conclusionsThis Delphi consensus provides pragmatic, physiology-driven recommendations for the management of NOAF in septic shock, supporting clinical decision-making in complex real-world settings where evidence remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.